influenza vaccine

Seqirus wins third FDA approval, enters two distribution agreements

As Seqirus hopes to recover from rocky 2016 financials, the company picked up some steam on both sides of the Atlantic this week. Within the span of a few days, the flu-focused company notched its second quadrivalent vaccine approval from the FDA and signed two marketing and distribution deals in Europe.